Sarah B Goldberg MD

Assistant Professor of Medicine, Medical Oncology

333 Cedar StFmp130New Haven, CT 06520
Phone+1 203-785-7564
Fax+1 203-785-3788

Dr. Goldberg is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goldberg's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2006 - 2009
Icahn School of Medicine at Mount SinaiClass of 2006

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2012 - 2026
MA State Medical License 2008 - 2013
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013, 2015-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017

Clinical Trials

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
COMPLETED
PHASE2
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
COMPLETED
PHASE2, PHASE3
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC Start of enrollment: 2022 Feb 10
TERMINATED
PHASE2

Publications & Presentations

PubMed

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line o...
Isamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, Jonathan W Goldman, Adrianus J de Langen
Lung Cancer. 2026-08-01
ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.
Paul Stockhammer, Talal El Zarif, Jacob L Schillo, Fangyong Li, Sarah B Goldberg
Journal of Thoracic Oncology. 2026-08-01
Treatment of Non-Small Cell Lung Cancer: A Clinical Model for Solid Tumors.
Sarah B Goldberg, Roy S Herbst
Cancer Journal. 2026-07-24

Journal Articles

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Guoping Cai, Sarah B Goldberg, Scott Gettinger, Anne Chiang, Roy S Herbst, David L Rimm, Kurt Schalper, Richard Lifton, Clinical Cancer Research

Lectures

Optimizing the Use of Immunotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018